Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04507607
Status:
UNKNOWN
Last Update Posted:
2020-12-22
First Post:
2020-07-18
Brief Title:
Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection
Sponsor:
Third Affiliated Hospital Sun Yat-Sen University
Organization:
Third Affiliated Hospital Sun Yat-Sen University
Study Overview
Official Title:
Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection
Status:
UNKNOWN
Status Verified Date:
2020-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The effectiveness of mother-to-child block of CHB in pregnant women in the middle and later stages of pregnancy has been recognized by the guidelines TAF as a newly marketed antiviral drug has not been conclusively concluded in terms of its efficacy and postpartum safety in preventing mother-to-child transmission in pregnant womenOur purpose is to explore the TAF for CHB the curative effect of pregnant and postnatal security
Detailed Description:
After diagnosis at the infection clinic of the Third Affiliated Hospital of Sun Yat-sen University the eligible patients were enrolled into the groupEach person will sign the informed consent prior to enrollment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None